HomeCompareAVES vs JNJ

AVES vs JNJ: Dividend Comparison 2026

AVES yields 3.22% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVES wins by $4.6K in total portfolio value
10 years
AVES
AVES
● Live price
3.22%
Share price
$59.34
Annual div
$1.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.6K
Annual income
$396.84
Full AVES calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — AVES vs JNJ

📍 AVES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVESJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVES + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVES pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVES
Annual income on $10K today (after 15% tax)
$274.08/yr
After 10yr DRIP, annual income (after tax)
$337.31/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $366.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVES + JNJ for your $10,000?

AVES: 50%JNJ: 50%
100% JNJ50/50100% AVES
Portfolio after 10yr
$22.3K
Annual income
$612.31/yr
Blended yield
2.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AVES
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVES buys
0
JNJ buys
0
No recent congressional trades found for AVES or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVESJNJ
Forward yield3.22%3.36%
Annual dividend / share$1.91$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$24.6K$20.0K
Annual income after 10y$396.84$827.78
Total dividends collected$3.6K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AVES vs JNJ ($10,000, DRIP)

YearAVES PortfolioAVES Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,022$322.45$10,676$355.77+$346.00AVES
2$12,126$332.16$11,407$389.39+$719.00AVES
3$13,317$341.52$12,198$426.53+$1.1KAVES
4$14,599$350.51$13,056$467.62+$1.5KAVES
5$15,980$359.13$13,987$513.12+$2.0KAVES
6$17,466$367.39$14,998$563.56+$2.5KAVES
7$19,064$375.28$16,098$619.52+$3.0KAVES
8$20,782$382.82$17,295$681.69+$3.5KAVES
9$22,626$390.00$18,599$750.82+$4.0KAVES
10$24,607$396.84$20,022$827.78+$4.6KAVES

AVES vs JNJ: Complete Analysis 2026

AVESStock

Invests in a broad set of companies of all market capitalizations across emerging markets countries and is designed to increase expected returns* by focusing on firms trading at what we believe are lower valuations with higher profitability ratios.**Pursues the benefits associated with indexing (diversification, low turnover, transparency of exposures), but with the ability to add value by making investment decisions using information in current prices.Efficient portfolio management and trading process that is designed to enhance returns while seeking to reduce unnecessary risks and costs for investors.Built to fit seamlessly into an investor's asset allocation.

Full AVES Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this AVES vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVES vs SCHDAVES vs JEPIAVES vs OAVES vs KOAVES vs MAINAVES vs ABBVAVES vs MRKAVES vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.